Author(s)

Lvping Fu, Shasha Zhou, Chen Yang, Weihua Qi, Zhiyuan Guo

Corresponding Author

Shasha Zhou

Abstract

Objective: Comparing the feasibility of recombinant human endostatin combined with the chemotherapy after microwave ablation versus for liver metastasis of gastric cancer.Methods: the Forty-eight patients with liver metastasis that are from gastric cancer were divided into two groups. 24 patients received chemotherapy which was combined with recombinant human endostatin after microwave ablation, and 24 patients received chemotherapy after microwave ablation, and the survival rate curative effect evaluation of the experimental group and the control group were compared.Results: The 1-and 2-years survival rates of the experimental group were 70.8% (17/24) and 33.3% (8/24), and the control group was 54.1% (13/24) and 20.8% (5/24). But the 1- and 2-year survival rates were better than control group of (X1² = 3.27, X2² = 4.32, P <0.05).Conclusion: The Recombinant human endostatin combined with chemotherapy after microwave ablation can effectively improve the clinical efficacy of gastric cancer liver metastasis.

Keywords

Gastric cancer liver metastasis; Recombinant human endostatin; Microwave ablation; Effect of Treatment